השוואת שיטות

	שאלון איכות חיים באקנה (Acne-QoL)	POEM (מדד ממוקד-מטופל לאקזמה)	Skindex-29 (כלי להערכת איכות חיים במחלות עור)
תחום	דרמטולוגיה	דרמטולוגיה	דרמטולוגיה
משפחה	Process / pipeline	Process / pipeline	Process / pipeline
שנת המקור	2004	2004	1997
הוגה השיטה	Halvorsen JA et al.	Charman CR, Venn AJ, Williams HC	Chren MM, Lasek RJ
סוג	Self-report	Self-report	Self-report
מקור מכונן	Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
כינויים	Acne-Q, Acne-Specific QoL	POEM Score	Skindex, Skindex-QoL
קשורות	4	2	1
תקציר	Acne-QoL is a disease-specific, patient-administered quality-of-life measure assessing the psychological and social burden of acne vulgaris. Acne is the most common skin disease in adolescents and young adults and causes substantial psychological distress, depression, anxiety, and social impairment disproportionate to its severity. Multiple versions of Acne-QoL exist (19–24 items); all capture emotional, social, and functional impacts. Acne-QoL is essential in clinical trials and observational studies to ensure treatment efficacy encompasses quality-of-life outcomes.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.